The influences of obesity and glycemic control on endothelial activation in patients with type 2 diabetes

被引:56
作者
Bagg, W
Ferri, C
Desideri, G
Gamble, G
Ockelford, P
Braatvedt, GD
机构
[1] Univ Auckland, Dept Med, Auckland 1000, New Zealand
[2] Univ Aquila, Dept Internal Med & Publ Hlth, I-67100 Laquila, Italy
关键词
D O I
10.1210/jc.86.11.5491
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aims of this study were to elucidate the factors that contribute to endothelial activation and fibrinolytic abnormalities in patients with poorly controlled type 2 diabetes and to determine whether improved glycemic control reduces endothelial activation. Adhesion molecules [E-selectin, intracellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1], von Willebrand factor, total nitric oxide (NO), endothelin-1, tissue plasminogen activator, and plasminogen activator inhibitor-1 were measured in 43 type 2 diabetic subjects with hemoglobin A(1c) of 9.0% or more at baseline (compared with 21 healthy controls) who after 20 wk had been randomized to either improved (IC) or usual (UC) glycemic control. At baseline, type 2 diabetic patients had significant endothelial activation and abnormal fibrinolysis compared with control subjects. Body mass index in the diabetic patients was the only independent predictor of E-selectin (P = 0.007), ICAM-1 (P = 0.01), and NO (P = 0.008) concentrations, but not vascular cell adhesion molecule-1, plasminogen activator inhibitor-1, or tissue plasminogen activator (all P > 0.05). Type 2 diabetic patients with a body mass index of 28 kg/m(2) or less had concentrations of E-selectin, ICAM-1, endothelin-1, and NO similar to those in healthy controls. After 20 wk, hemoglobin Ai, was significantly lower in IC us. UC (IC, 8.02 +/- 0.25%; UC, 10.23 +/- 0.23%; P < 0.0001), but there were no significant changes in markers of endothelial activation or indexes of fibrinolysis. Obesity appears to be the most important predictor of endothelial activation in patients with type 2 diabetes. Shortterm improvement in glycemic control does not appear to reduce endothelial activation.
引用
收藏
页码:5491 / 5497
页数:7
相关论文
共 40 条
[1]   Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity [J].
Arcaro, G ;
Zamboni, M ;
Rossi, L ;
Turcato, E ;
Covi, G ;
Armellini, F ;
Bosello, O ;
Lechi, A .
INTERNATIONAL JOURNAL OF OBESITY, 1999, 23 (09) :936-942
[2]  
BAGG W, INT MED J, V31, P322
[3]   Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects -: The BIGPRO1 study [J].
Charles, MA ;
Morange, P ;
Eschwège, E ;
André, P ;
Vague, P ;
Juhan-Vague, I .
DIABETES CARE, 1998, 21 (11) :1967-1972
[4]   MEASURING THE ALBUMIN EXCRETION RATE - AGREEMENT BETWEEN METHODS AND BIOLOGICAL VARIABILITY [J].
CUNDY, TF ;
NIXON, D ;
BERKAHN, L ;
BAKER, J .
DIABETIC MEDICINE, 1992, 9 (02) :138-143
[5]   Role of plasma and urinary endothelin-l in early diabetic and hypertensive nephropathy [J].
De Mattia, G ;
Cassone-Faldetta, M ;
Bellini, C ;
Bravi, MC ;
Laurenti, O ;
Baldoncini, R ;
Santucci, A ;
Ferri, C .
AMERICAN JOURNAL OF HYPERTENSION, 1998, 11 (08) :983-988
[6]   Endothelial dysfunction in diabetes [J].
De Vriese, AS ;
Verbeuren, TJ ;
Van de Voorde, J ;
Lameire, NH ;
Vanhoutte, PM .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (05) :963-974
[7]   Effects of ACE inhibition on spontaneous and insulin-stimulated endothelin-1 secretion - In vitro and in vivo studies [J].
Desideri, G ;
Ferri, C ;
Bellini, C ;
DeMattia, G ;
Santucci, A .
DIABETES, 1997, 46 (01) :81-86
[8]   Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications -: The effect of α-tocopherol supplementation [J].
Devaraj, S ;
Jialal, I .
CIRCULATION, 2000, 102 (02) :191-196
[9]   THE CASE FOR USING WAIST TO HIP RATIO MEASUREMENTS IN ROUTINE MEDICAL CHECKS [J].
EGGER, G .
MEDICAL JOURNAL OF AUSTRALIA, 1992, 156 (04) :280-285
[10]   Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities [J].
Ferri, C ;
Desideri, G ;
Baldoncini, R ;
Bellini, C ;
De Angelis, C ;
Mazzocchi, C ;
Santucci, A .
DIABETES, 1998, 47 (04) :660-667